European shares were unchanged on Friday, as losses in heavyweight healthcare shares were countered by an advance in oil and ...

The Sensex dropped 502 points on Friday to close at 81,758, while the Nifty slipped 143 points to end below the 25,000 mark ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

The Nikkei 225 has fallen 0.2%, while the Hang Seng index is 0.3% higher. The FTSE 100 index is seen opening about 21 points ...

GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

GSK (GSK) faces an investigation from U.S. Senator Maggie Hassan over its decision to discontinue Flovent HFA asthma inhaler last year. Read more here.

Senator Maggie Hassan is investigating GSK's discontinuation of Flovent HFA, citing increased hospitalizations, higher drug costs, and lost Medicaid rebates.